Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Our blood consists of many cell types that develop through different stages from a precursor type—the blood stem cell. An ...

Patients with low and high risk for PEP and native papilla were randomly allocated (1:1) to receive 100 mg diclofenac or 100 ... or means and SDs and t-test were performed as appropriate. Comparison ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive officer and co-founder of Teclison ...

Healthcare professionals need better support to help recognize and treat symptoms of disordered eating in people living with ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...